Pascal Announces the Appointment of a New Director, Dr. Graeme I. Bell
06 Dezember 2017 - 12:42AM
Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX
VENTURE:PAS), a biotechnology company that specializes in cancer
drug discovery and development, today announced the appointment of
Dr. Graeme I. Bell to its Board of Directors.
Dr. Bell received his BSc and MSc degrees from
the University of Calgary and his PhD from the University of
California, San Francisco. He is currently the Kovler Family
Distinguished Service Professor in Medicine, and Human Genetics at
the University of Chicago. Dr. Bell is a member of the National
Academy of Medicine and the American Academy of Arts and Sciences.
For his pioneering work on the genetics of diabetes, he was awarded
the 2013 Banting Medal for Scientific Achievement Award, the
highest scientific honor from the American Diabetes Association.
This prize is awarded annually in memory of the Canadian medical
scientist Sir Frederick Banting, Nobel laureate who was one of the
key investigators that discovered insulin.
“Dr. Bell is an exceptional medical scientist,
and we are very pleased to have him join our Board,” said Dr.
Patrick Gray, CEO of Pascal. “In addition to his distinguished and
decorated career in medicine, Dr. Bell’s work has been the focus of
entrepreneurial biotech startups. His significant insights will be
invaluable as we develop novel therapeutics for cancer and advance
these through clinical development.”
Dr. Bell has been honored with numerous
additional awards recognizing his seminal contributions to the
understanding of diabetes and metabolic disease. He gained
recognition early in his career for the cloning of the human
insulin gene, a landmark achievement that paved the way for the
production of recombinant insulin. Demonstrating his
entrepreneurial spirit, he became a founding scientist at Chiron, a
leading biotechnology company that was later acquired by
Novartis. He has also been a founder and advisor for other
biotech startups.
This appointment is subject to the TSXV
approval.
On Behalf of the Board of DirectorsPatrick W. Gray, President
& CEO
Company Contact: Dr. Patrick GrayTel:
1-206-650-6765
Certain statements in this press release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 or forward-looking
information under applicable Canadian securities legislation that
may not be based on historical fact, including without limitation
statements containing the words “believe”, “may”, “plan”, “will”,
“estimate”, “continue”, “anticipate”, “intend”, “expect” and
similar expressions. Such forward-looking statements or information
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, events or developments, or
industry results, to be materially different from any future
results, events or developments express or implied by such
forward-looking statements or information. Such factors include,
among others, our stage of development, lack of any product
revenues, additional capital requirements, risk associated with the
completion of clinical trials and obtaining regulatory approval to
market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects
for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and
uncertainties that could cause such actual events or results
expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
“Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release”
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Pascal Biosciences (TSXV:PAS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Pascal Biosciences (TSXV:PAS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024